Tumor Location Prognostic and Predictive in KRAS wt mCRC: Retrospective Analysis of CALGB/SWOG 80405

June 3-7, 2016; Chicago, Illinois
Tumor location appears to be prognostic of PFS, OS, and predictive of response to biologic agents in KRAS wt mCRC.
Format: Microsoft PowerPoint (.ppt)
File Size: 606 KB
Released: June 8, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

In this slideset from Clinical Care Options (CCO), experts discuss their thoughts on dosing of regorafenib and TAS-102 for colorectal cancer (CRC).

Kanwal Raghav, MD person default Rachel Riechelmann, MD, PhD Released: October 21, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue